RecruitingNot ApplicableNCT05655078

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

Sponsor

University College, London

Enrollment

148 participants

Start Date

Mar 28, 2024

Study Type

INTERVENTIONAL

Conditions

Malignant Pleural Mesothelioma

Summary

Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether using proton beam therapy (a precise form of radiation) to treat one entire side of the chest is safe and effective for people with malignant pleural mesothelioma (a cancer of the lining of the lungs, often linked to asbestos exposure) who are being monitored rather than receiving immediate chemotherapy. **You may be eligible if...** - You are 18 or older and have a confirmed diagnosis of malignant pleural mesothelioma - Your cancer is confined to one side of the chest - Your cancer has not spread to lymph nodes beyond the chest or to distant sites (N0/N1, M0) - Your lung function is adequate (at least 40% of predicted capacity) - You and your medical team have chosen to delay chemotherapy and watch the cancer closely - You are able to travel to a proton therapy center if randomized to that group **You may NOT be eligible if...** - Your cancer has spread to the other side of the chest or to distant organs - Your lung function is too impaired for the treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONProton beam therapy

5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).

Locations(25)

East Sussex Healthcare NHS Trust - Eastbourne Hospital

Eastbourne, East Sussex, United Kingdom

East Sussex Healthcare NHS Trust - Conquest Hospital

Saint Leonards-on-Sea, East Sussex, United Kingdom

Royal Berkshire Hospital

Reading, England, United Kingdom

Southend University Hospital

Southend, Essex, United Kingdom

Queen Alexandra Hospital

Portsmouth, Hampshire, United Kingdom

Queen Elizabeth Hospital, King's Lynn

Kings Lynn, Norfolk, United Kingdom

Furness General Hospital

Barrow in Furness, United Kingdom

Betsi Cadwaladr University Health Board -Glan Clwyd Hospital

Bodelwyddan, United Kingdom

Southmead Hospital

Bristol, United Kingdom

Addenbrooke's Hospital

Cambridge, United Kingdom

Velindre Cancer Centre

Cardiff, United Kingdom

Broomfield Hospital

Chelmsford, United Kingdom

Queens Centre, Castle Hill Hospital

Hull, United Kingdom

Royal Lancaster Hospital

Lancaster, United Kingdom

St James University Hospital

Leeds, United Kingdom

Leicester Royal Infirmary

Leicester, United Kingdom

Clatterbridge Cancer Centre

Liverpool, United Kingdom

St Bartholomew's Hospital

London, United Kingdom

University College London Hospital

London, United Kingdom

Maidstone Hospital

Maidstone, United Kingdom

Christie Hospital

Manchester, United Kingdom

Wythenshawe Hospital

Manchester, United Kingdom

Freeman Hospital

Newcastle upon Tyne, United Kingdom

Weston Park Cancer Centre

Sheffield, United Kingdom

Torbay Hospital

Torquay, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05655078

Related Trials

The IMmunotherapy Pleural 5-ALA PDT

NCT044005391 location

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

NCT060379417 locations

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

NCT063182861 location

Hemithoracic Arc Radiotherapy Post Pleural Decortication

NCT069104491 location

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

NCT057650843 locations